HIV AIDS

A new rapid HIV test accurately differentiates vaccine-induced false positives from active HIV-1 infection, potentially improving diagnostics and vaccine trials.

Formulary restrictions and prior authorization requirements block access to newer PrEP options, while cost sharing over $50 cuts dispensing odds by 93%.

Merck reveals promising phase 3 results for DOR/ISL, showing minimal impact on weight and lipids in adults with suppressed HIV-1.

Merck has launched phase 3 trials for MK-8527, a promising once-monthly HIV prevention pill, aiming to enhance PrEP options globally.

New findings showcase the transformative impact of long-acting injectable therapies for effective HIV treatment and prevention.

The only pre-exposure prophylaxis approved for twice-a-year dosing, lenacapavir "could be the transformative PrEP option we’ve been waiting for," one expert said.

CROI 2025: Increased HPV vaccine coverage could reduce HIV cases by thousands, according to a new study.

Get a quick overview of recommendations for preventive health services and screenings focused on the unique needs of women across the lifespan.

Your daily dose of the clinical news you may have missed.

IDWeek 2023. New study found just slightly more than half of prescriptions for cabotegravir for HIV PrEP resulted in at least 1 injection, suggesting limitations in use and access to the injectable HIV integrase inhibitor.

IDWeek 2023: In a large cohort of people living with HIV, those switching from oral ART to long acting CAB+RPV were more than 4x as likely to adhere to the regimen.

Approved for persons with HIV with undetectable VL, CAB+RPV LA may also be appropriate for those with VL ≥50 copies when the therapy is initiated, according to new findings.

IDWeek 2023: Leading physician scientists will headline plenary sessions and named lectureships on topics ranging from antibiotic stewardship to artificial intelligence.

The USPSTF particularly emphasizes effective communication with patients, including adherence support and calls for reducing barriers to PrEP for racial, ethnic, and other minority groups.

Patient Care Guideline Toplines summarize newly revised and updated clinical recommendations from professional societies for convenient, at-a-glance review.

Lenacapavir is the first of a new class of antiretrovirals, and it is indicated for persons with multidrug resistance, intolerance, or safety considerations.

New data showed a sharp drop in HIV tests administered in health care and non-health care settings from 2019 to 2020—primarily among persons disproportionately affected by HIV.

Persons with HIV now have the option to forego initiation of the long-acting injectable with oral formulations of the medications, according to a statement from Viiv Healthcare.

New study suggests HIV-1 infection is more virulent when transmitted through heterosexual penile-vaginal intercourse than through anal intercourse between men who have sex with men due to transmission bottlenecks.

The CDC update recommends that clinicians advise all sexually active patients about PrEP and includes a new section on prescribing injectable bimonthly cabotegravir.

Get 90% of all HIV-infected persons diagnosed, get 90% of them on ART, and get 90% of those on ART “undetectable.” Are we there yet?

The AAP updated its guidance to recommend routine HIV screening at least once in all adolescents aged ≥15 years and at-risk youth be rescreened annually.

Nearly 25% of patients with HIV who use antiretroviral therapy will reach 65 years of age or older by 2030, researchers projected in a new analysis.

IDWeek 2021: Despite declining mortality rates among patients with HIV in the past 2 decades, a new study finds significant disparities in gender and race.

Viral-load monitoring rates decreased and clinic visits declined overall despite an increase in use of telehealth.